Dietary_JJ Intakes_NP of_IN Fat_NP and_CC Risk_NP of_IN Parkinson_NP 's_POS Disease_NP Honglei_NP Chen1_NP ,_, ,_, Shumin_NP M._NP Zhang2,3_NP ,_, Miguel_NP A._NP Hern√°n2_NP ,_, Walter_NP C._NP Willett1,2,4_NP and_CC Alberto_NP Ascherio1,2,4_NP 1_CD Department_NP of_IN Nutrition_NP ,_, Harvard_NP School_NP of_IN Public_NP Health_NP ,_, Boston_NP ,_, MA_NP ._SENT 2_CD Department_NP of_IN Epidemiology_NP ,_, Harvard_NP School_NP of_IN Public_NP Health_NP ,_, Boston_NP ,_, MA_NP ._SENT 3_CD Division_NN of_IN Preventive_NP Medicine_NP ,_, Department_NP of_IN Medicine_NP ,_, Brigham_NP and_CC Women_NP 's_POS Hospital_NP and_CC Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, MA_NP ._SENT 4_CD Channing_NP Laboratory_NP ,_, Department_NP of_IN Medicine_NP ,_, Brigham_NP and_CC Women_NP 's_POS Hospital_NP and_CC Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, MA_NP ._SENT Received_VBN for_IN publication_NN July_NP 2_CD ,_, 2002_CD ;_: accepted_VBN for_IN publication_NN December_NP 2_CD ,_, 2002_CD ._SENT ABSTRACT_JJ TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP Previous_JJ epidemiologic_JJ studies_NNS have_VBP generated_VBN inconsistent_JJ results_NNS regarding_VBG the_DT associations_NNS between_IN fat_JJ intakes_NNS and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT The_DT authors_NNS investigated_VBD these_DT associations_NNS in_IN two_CD large_JJ ,_, prospective_JJ US_NP cohorts_NNS ._SENT They_PP documented_VBD 191_CD incident_NN cases_NNS of_IN Parkinson_NP 's_POS disease_NN in_IN men_NNS (_( 1986-1998_CD )_) and_CC 168_CD in_IN women_NNS (_( 1980-1998_CD )_) during_IN the_DT follow-up_NN ._SENT Overall_RB ,_, intakes_NNS of_IN total_JJ fat_JJ or_CC major_JJ types_NNS of_IN fat_NN were_VBD not_RB significantly_RB associated_VBN with_IN the_DT risk_NN ._SENT The_DT relative_JJ risks_NNS comparing_VBG the_DT highest_JJS quintile_NN of_IN animal_JJ fat_JJ intake_NN with_IN the_DT lowest_JJS were_VBD 1.42_CD for_IN men_NNS (_( 95_CD %_NN confidence_NN interval_NN (_( CI_NP )_) :_: 0.91_CD ,_, 2.20_CD ;_: p_NN for_IN trend_NN =_SYM 0.1_CD )_) and_CC 0.65_CD for_IN women_NNS (_( 95_CD %_NN CI_NP :_: 0.36_CD ,_, 1.16_CD ;_: p_NN for_IN trend_NN =_SYM 0.3_CD )_) ._SENT For_IN men_NNS ,_, but_CC not_RB women_NNS ,_, replacement_NN of_IN polyunsaturated_JJ fat_NN with_IN saturated_JJ fat_NN was_VBD associated_VBN with_IN a_DT significantly_RB increased_VBN risk_NN (_( 5_CD %_NN of_IN energy_NN intake_NN ,_, relative_JJ risk_NN (_( RR_NP )_) =_SYM 1.83_CD ,_, 95_CD %_NN CI_NP :_: 1.10_CD ,_, 3.03_CD )_) ._SENT Of_IN the_DT individual_JJ polyunsaturated_JJ fatty_JJ acids_NNS ,_, arachidonic_JJ acid_NN tended_VBN to_TO be_VB inversely_RB associated_VBN with_IN the_DT risk_NN (_( pooled_VBN RR_NP between_IN extreme_JJ quintiles_NNS =_SYM 0.65_CD ,_, 95_CD %_NN CI_NP :_: 0.46_CD ,_, 0.91_CD ;_: p_NN for_IN trend_NN =_SYM 0.05_CD )_) ._SENT Results_NNS do_VBP not_RB support_VB an_DT important_JJ role_NN of_IN overall_JJ fat_JJ intake_NN in_IN the_DT pathogenesis_NN of_IN Parkinson_NP 's_POS disease_NN ,_, but_CC a_DT possible_JJ adverse_JJ effect_NN of_IN saturated_JJ fat_NN for_IN men_NNS could_MD not_RB be_VB excluded_VBN ._SENT dietary_JJ fats_NNS ;_: Parkinson_NPS disease_NN ;_: prospective_JJ studies_NNS Abbreviations_NNS :_: Abbreviations_NNS :_: CI_NP ,_, confidence_NN interval_NN ;_: FFQ_NP ,_, food_NN frequency_NN questionnaire_NN ;_: RR_NP ,_, relative_JJ risk_NN ._SENT INTRODUCTION_NN TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP Mitochondria_NP dysfunction_NN and_CC oxidative_JJ stress_NN are_VBP thought_VBN to_TO contribute_VB to_TO dopaminergic_NN neuron_NN death_NN in_IN Parkinson_NP 's_POS disease_NN (_( 1_CD ,_, 2_CD )_) ._SENT Fatty_JJ acids_NNS are_VBP important_JJ in_IN maintaining_VBG the_DT structure_NN and_CC permeability_NN of_IN cell_NN membranes_NNS ,_, and_CC a_DT high_JJ concentration_NN of_IN polyunsaturated_JJ fatty_JJ acid_NN may_MD contribute_VB to_TO neural_JJ oxidative_JJ stress_NN through_IN lipid_NN peroxidation_NN ._SENT Previous_JJ epidemiologic_JJ studies_NNS (_( 3-9_CD )_) have_VBP generated_VBN inconsistent_JJ results_NNS on_IN the_DT relations_NNS of_IN dietary_JJ fat_NN to_TO risk_VB of_IN Parkinson_NP 's_POS disease_NN ._SENT All_DT but_CC one_CD (_( 6_CD )_) of_IN these_DT investigations_NNS used_VBD a_DT retrospective_JJ case-control_NN design_NN ,_, which_WDT is_VBZ not_RB well_RB suited_VBN for_IN investigating_VBG the_DT dietary_JJ etiology_NN of_IN chronic_JJ disease_NN because_IN of_IN the_DT potential_NN for_IN recall_NN and_CC selection_NN biases_NNS (_( 10_CD )_) and_CC the_DT difficulty_NN in_IN controlling_VBG for_IN the_DT effects_NNS that_IN disease_NN status_NN itself_PP may_MD have_VB on_IN diet_NN ._SENT Therefore_RB ,_, we_PP examined_VBD prospectively_RB the_DT associations_NNS between_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN and_CC intakes_NNS of_IN total_JJ fat_NN ,_, specific_JJ types_NNS of_IN fat_JJ ,_, and_CC other_JJ macronutrients_NNS in_IN two_CD large_JJ US_NP cohorts_NNS ,_, the_DT Health_NP Professionals_NP Follow-up_NP Study_NP and_CC the_DT Nurses_NP '_POS Health_NP Study_NP ._SENT MATERIALS_NNS AND_CC METHODS_NP TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP Study_NP population_NN The_DT Health_NP Professionals_NP Follow-up_NP Study_NP cohort_NN was_VBD established_VBN in_IN 1986_CD ,_, when_WRB 51,529_CD male_JJ health_NN professionals_NNS (_( dentists_NNS ,_, optometrists_NNS ,_, pharmacists_NNS ,_, osteopaths_NNS ,_, podiatrists_NNS ,_, and_CC veterinarians_NNS )_) aged_VBN 40-75_CD years_NNS responded_VBD to_TO a_DT mailed_VBN questionnaire_NN that_WDT included_VBD a_DT 131-item_JJ food_NN frequency_NN questionnaire_NN (_( FFQ_NP )_) (_( 11_CD )_) in_IN addition_NN to_TO questions_NNS on_IN disease_NN history_NN and_CC lifestyle_NN ._SENT Dietary_JJ information_NN was_VBD updated_VBN in_IN 1990_CD and_CC 1994_CD with_IN similar_JJ FFQs_NP ._SENT The_DT Nurses_NP '_POS Health_NP Study_NP cohort_NN was_VBD established_VBN in_IN 1976_CD ,_, when_WRB 121,700_CD registered_JJ nurses_NNS in_IN 11_CD US_NP states_NNS aged_VBN 30-55_CD years_NNS provided_VBD detailed_JJ information_NN about_IN their_PP$ medical_JJ history_NN and_CC lifestyle_NN practices_NNS (_( 12_CD )_) ._SENT A_DT 61-item_JJ FFQ_NP was_VBD first_RB administered_VBN to_TO the_DT Nurses_NP '_POS Health_NP Study_NP participants_NNS in_IN 1980_CD ,_, and_CC expanded_VBD FFQs_NP were_VBD used_VBN in_IN 1984_CD ,_, 1986_CD ,_, 1990_CD ,_, and_CC 1994_CD ._SENT In_IN both_DT cohorts_NNS ,_, follow-up_NN questionnaires_NNS are_VBP mailed_VBN to_TO participants_NNS every_DT 2_CD years_NNS to_TO update_VB information_NN on_IN potential_JJ risk_NN factors_NNS for_IN chronic_JJ diseases_NNS and_CC to_TO ascertain_VB whether_IN major_JJ medical_JJ events_NNS have_VBP occurred_VBN ._SENT A_DT specific_JJ question_NN on_IN lifetime_NN occurrence_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD first_RB included_VBN in_IN the_DT 1988_CD (_( Health_NP Professionals_NP Follow-up_NP Study_NP )_) and_CC 1994_CD (_( Nurses_NP '_POS Health_NP Study_NP )_) questionnaires_NNS ,_, and_CC a_DT question_NN on_IN a_DT Parkinson_NPS 's_POS disease_NN diagnosis_NN within_IN the_DT previous_JJ 2_CD years_NNS was_VBD asked_VBN in_IN the_DT subsequent_JJ questionnaires_NNS ._SENT Participants_NNS who_WP had_VBD been_VBN diagnosed_VBN with_IN Parkinson_NP 's_POS disease_NN ,_, stroke_NN ,_, or_CC cancer_NN (_( other_JJ than_IN nonmelanoma_NN skin_NN cancer_NN )_) at_IN baseline_NN were_VBD excluded_VBN from_IN the_DT analyses_NNS ._SENT In_IN addition_NN ,_, we_PP excluded_VBD participants_NNS whose_WP$ daily_JJ energy_NN intakes_NNS were_VBD extreme_JJ (_( <800_or 4,200_CD kcal_NN for_IN men_NNS ;_: <500_or 3,500_CD kcal_NN for_IN women_NNS )_) or_CC for_IN whom_WP the_DT FFQ_NP was_VBD incomplete_JJ at_IN baseline_NN (_( >70_JJ blank_JJ responses_NNS for_IN men_NNS and_CC >10_NN for_IN women_NNS )_) ._SENT We_PP followed_VBD 47,331_CD eligible_JJ men_NNS and_CC 88,563_CD eligible_JJ women_NNS from_IN baseline_NN (_( 1986_CD and_CC 1980_CD ,_, respectively_RB )_) to_TO 1998_CD or_CC date_NN of_IN Parkinson_NP 's_POS disease_NN diagnosis_NN or_CC death_NN ,_, whichever_WDT occurred_VBD first_JJ ._SENT These_DT studies_NNS were_VBD approved_VBN by_IN the_DT Human_NP Subjects_NP Research_NP Committees_NNS at_IN the_DT Harvard_NP School_NP of_IN Public_NP Health_NP and_CC the_DT Brigham_NP and_CC Women_NP 's_POS Hospital_NP in_IN Boston_NP ,_, Massachusetts_NP ._SENT Case_NN ascertainment_NN Ascertainment_NN of_IN the_DT Parkinson_NPS 's_POS disease_NN cases_NNS in_IN this_DT study_NN has_VBZ been_VBN described_VBN previously_RB (_( 13_CD )_) ._SENT Briefly_RB ,_, after_IN obtaining_VBG permission_NN from_IN participants_NNS who_WP reported_VBD a_DT new_JJ diagnosis_NN of_IN Parkinson_NP 's_POS disease_NN ,_, we_PP asked_VBD the_DT treating_VBG neurologist_NN (_( or_CC the_DT internist_NN if_IN the_DT neurologist_NN did_VBD not_RB respond_VB )_) to_TO complete_VB a_DT questionnaire_NN to_TO confirm_VB the_DT diagnosis_NN of_IN Parkinson_NP 's_POS disease_NN and_CC the_DT certainty_NN of_IN the_DT diagnosis_NN or_CC to_TO supply_VB a_DT copy_NN of_IN the_DT medical_JJ record_NN ._SENT A_DT case_NN was_VBD confirmed_VBN if_IN a_DT diagnosis_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD considered_VBN definite_JJ or_CC probable_JJ by_IN the_DT treating_VBG neurologist_NN or_CC internist_NN or_CC if_IN the_DT medical_JJ record_NN included_VBD either_CC a_DT final_JJ diagnosis_NN of_IN Parkinson_NP 's_POS disease_NN made_VBD by_IN a_DT neurologist_NN or_CC evidence_NN at_IN a_DT neurologic_JJ examination_NN of_IN at_IN least_JJS two_CD of_IN the_DT three_CD cardinal_JJ signs_NNS of_IN the_DT disease_NN (_( rest_NN tremor_NN ,_, rigidity_NN ,_, bradykinesia_NP )_) in_IN the_DT absence_NN of_IN features_NNS suggesting_VBG other_JJ diagnoses_NNS ._SENT The_DT investigators_NNS ,_, blinded_VBN to_TO exposure_NN status_NN ,_, reviewed_VBD the_DT medical_JJ records_NNS ._SENT Overall_RB ,_, the_DT diagnosis_NN was_VBD confirmed_VBN by_IN the_DT treating_VBG neurologist_NN for_IN 82.3_CD percent_NN of_IN the_DT cases_NNS ,_, by_IN review_NN of_IN the_DT medical_JJ records_NNS for_IN 3.1_CD percent_NN of_IN the_DT cases_NNS ,_, and_CC by_IN the_DT treating_VBG internist_NN without_IN further_JJR support_NN for_IN the_DT remaining_VBG 14.6_CD percent_NN of_IN the_DT cases_NNS ._SENT Deaths_NNS in_IN the_DT cohorts_NNS were_VBD reported_VBN by_IN family_NN members_NNS ,_, coworkers_NNS ,_, or_CC postal_JJ authorities_NNS ,_, or_CC they_PP were_VBD identified_VBN by_IN searching_VBG the_DT National_NP Death_NP Index_NP ._SENT If_IN Parkinson_NP 's_POS disease_NN was_VBD listed_VBN as_IN a_DT cause_NN of_IN death_NN on_IN the_DT death_NN certificate_NN ,_, we_PP requested_VBD permission_NN from_IN the_DT family_NN to_TO contact_VB the_DT treating_VBG neurologist_NN or_CC physician_NN and_CC followed_VBD the_DT same_JJ procedure_NN as_IN for_IN the_DT nonfatal_NN cases_NNS ._SENT Fewer_JJR than_IN 2_CD percent_NN of_IN the_DT cases_NNS were_VBD ascertained_VBN by_IN reviewing_VBG death_NN certificates_NNS ._SENT Exposure_NN assessment_NN For_IN each_DT item_NN on_IN the_DT FFQ_NP ,_, participants_NNS were_VBD asked_VBN how_WRB often_RB ,_, on_IN average_NN ,_, they_PP had_VBD consumed_VBN a_DT specified_JJ amount_NN during_IN the_DT previous_JJ 12_CD months_NNS ;_: possible_JJ response_NN categories_NNS were_VBD nine_CD and_CC ranged_VBD from_IN "_`` never_RB "_'' to_TO "_`` 6_CD or_CC more_JJR times_NNS per_IN day_NN ._SENT "_`` We_PP also_RB asked_VBD questions_NNS about_IN the_DT types_NNS of_IN fat_NN or_CC oil_NN used_VBN in_IN the_DT preparation_NN of_IN foods_NNS or_CC at_IN the_DT table_NN ._SENT The_DT nutrient_JJ composition_NN of_IN foods_NNS was_VBD estimated_VBN by_IN using_VBG the_DT Harvard_NP University_NP Food_NP Composition_NP Database_NP derived_VBD from_IN the_DT US_NP Department_NP of_IN Agriculture_NP (_( 14_CD ,_, 15_CD )_) and_CC was_VBD supplemented_VBN with_IN information_NN from_IN manufacturers_NNS (_( 11_CD )_) and_CC data_NNS from_IN peer-reviewed_JJ literature_NN ._SENT Dietary_JJ intakes_NNS assessed_VBN by_IN using_VBG the_DT Health_NP Professionals_NP Follow-up_NP Study_NP questionnaire_NN have_VBP been_VBN validated_VBN previously_RB among_IN 127_CD men_NNS ,_, who_WP had_VBD also_RB completed_VBN two_CD 1-week_NN weighed_VBD dietary_JJ records_NNS (_( 11_CD )_) ._SENT After_IN correction_NN for_IN day-to-day_JJ variability_NN ,_, the_DT Pearson_NP 's_POS correlation_NN coefficients_NNS were_VBD 0.67_CD for_IN total_JJ fat_NN ,_, 0.75_CD for_IN saturated_JJ fat_NN ,_, 0.37_CD for_IN polyunsaturated_JJ fat_NN ,_, 0.68_CD for_IN monounsaturated_JJ fat_NN ,_, and_CC 0.76_CD for_IN cholesterol_NN ._SENT In_IN the_DT Nurses_NP '_POS Health_NP Study_NP cohort_NN ,_, similar_JJ validation_NN studies_NNS were_VBD performed_VBN for_IN the_DT 1980_NP FFQ_NP (_( 16_CD )_) and_CC the_DT 1986_NP FFQ_NP (_( 10_CD )_) ._SENT The_DT corresponding_JJ 1980/1986_CD correlation_NN coefficients_NNS were_VBD 0.53/0.57_CD for_IN total_JJ fat_NN ,_, 0.59/0.68_CD for_IN saturated_JJ fat_NN ,_, 0.48/0.48_CD for_IN polyunsaturated_JJ fat_NN ,_, and_CC 0.61/0.73_CD for_IN cholesterol_NN ._SENT In_IN addition_NN ,_, intakes_NNS of_IN poly-_NN and_CC trans-unsaturated_JJ fatty_JJ acids_NNS calculated_VBN from_IN the_DT FFQ_NP were_VBD compared_VBN with_IN their_PP$ concentrations_NNS in_IN adipose_JJ tissue_NN (_( 17_CD ,_, 18_CD )_) ;_: the_DT correlations_NNS between_IN intake_NN as_IN a_DT proportion_NN of_IN fat_NN and_CC the_DT proportion_NN in_IN adipose_JJ tissue_NN for_IN men/women_NNS were_VBD 0.43/0.40_CD for_IN polyunsaturated_JJ fat_NN and_CC 0.34/0.40_CD for_IN trans-unsaturated_JJ fat_NN ._SENT We_PP used_VBD the_DT 1984_CD intakes_NNS assessed_VBN in_IN the_DT Nurses_NP '_POS Health_NP Study_NP as_IN the_DT baseline_JJ data_NNS for_IN analyses_NNS involving_VBG specific_JJ polyunsaturated_JJ fatty_JJ acids_NNS because_IN they_PP provided_VBD greater_JJR details_NNS to_TO calculate_VB intakes_NNS of_IN these_DT nutrients_NNS ._SENT Statistical_NP analyses_VBZ Macronutrient_JJ intakes_NNS were_VBD expressed_VBN as_IN percentage_NN of_IN energy_NN ,_, and_CC quintile_NN categories_NNS were_VBD used_VBN in_IN the_DT main_JJ analyses_NNS ._SENT Relative_JJ risks_NNS were_VBD calculated_VBN by_IN dividing_VBG the_DT incidence_NN rate_NN in_IN an_DT exposure_NN category_NN by_IN the_DT corresponding_JJ rate_NN in_IN the_DT reference_NN category_NN ._SENT Age-_NP and_CC smoking-adjusted_JJ relative_JJ risks_NNS were_VBD calculated_VBN by_IN using_VBG the_DT Mantel-Haenszel_NP method_NN (_( 19_CD )_) ._SENT The_DT multivariate-adjusted_JJ relative_JJ risks_NNS were_VBD derived_VBN from_IN a_DT pooled_JJ logistic_JJ regression_NN model_NN ._SENT In_IN this_DT model_NN ,_, each_DT 2-year_JJ interval_NN of_IN follow-up_NN is_VBZ considered_VBN as_IN a_DT separate_JJ cohort_NN ;_: the_DT observations_NNS from_IN each_DT of_IN these_DT cohorts_NNS are_VBP pooled_VBN into_IN a_DT single_JJ large_JJ population_NN ,_, and_CC the_DT analyses_NNS are_VBP conducted_VBN by_IN logistic_JJ regression_NN (_( 20_CD )_) ._SENT This_DT method_NN has_VBZ been_VBN shown_VBN to_TO be_VB equivalent_JJ to_TO a_DT Cox_NP proportional_JJ hazards_NNS analysis_NN when_WRB the_DT probability_NN of_IN an_DT event_NN within_IN each_DT interval_NN is_VBZ small_JJ (_( 20_CD )_) ._SENT Covariates_NNS adjusted_VBN for_IN in_IN the_DT models_NNS included_VBD age_NN ,_, smoking_NN status_NN ,_, total_JJ energy_NN intake_NN ,_, caffeine_NN intake_NN ,_, and_CC alcohol_NN consumption_NN ._SENT Because_IN the_DT age-_NN and_CC smoking-adjusted_JJ relative_JJ risks_NNS were_VBD similar_JJ to_TO the_DT multivariate_JJ relative_JJ risks_NNS ,_, the_DT latter_NN are_VBP presented_VBN in_IN this_DT paper_NN for_IN simplicity_NN ._SENT The_DT effects_NNS of_IN isocaloric_JJ substitution_NN of_IN polyunsaturated_JJ fat_NN with_IN saturated_JJ fat_NN were_VBD estimated_VBN by_IN fitting_VBG the_DT multivariate_JJ models_NNS with_IN saturated_JJ fat_JJ intake_NN as_IN a_DT continuous_JJ variable_NN and_CC adjusting_VBG for_IN total_JJ energy_NN intake_NN and_CC all_DT other_JJ sources_NNS of_IN energy_NN except_IN for_IN polyunsaturated_JJ fat_NN (_( 21_CD )_) ._SENT Log_VB relative_JJ risks_NNS from_IN the_DT two_CD cohorts_NNS were_VBD pooled_VBN by_IN the_DT inverse_NN of_IN their_PP$ variances_NNS ._SENT All_DT p_NN values_NNS were_VBD two_CD tailed_VBN ._SENT Primary_JJ analyses_NNS involved_VBD use_NN of_IN baseline_JJ intakes_NNS ._SENT However_RB ,_, we_PP also_RB took_VBD advantage_NN of_IN the_DT repeated_JJ dietary_JJ assessment_NN by_IN using_VBG the_DT cumulative_JJ average_JJ intakes_NNS from_IN all_DT available_JJ questionnaires_NNS prior_RB to_TO the_DT beginning_NN of_IN each_DT 2-year_JJ follow-up_NN period_NN (_( 22_CD )_) ._SENT The_DT cumulative_JJ average_NN was_VBD calculated_VBN ,_, for_IN example_NN ,_, for_IN men_NNS in_IN 1990_CD as_IN the_DT average_NN of_IN the_DT 1986_CD and_CC 1990_CD intakes_NNS and_CC for_IN men_NNS in_IN 1994_CD as_IN the_DT average_NN of_IN the_DT 1986_CD ,_, 1990_CD ,_, and_CC 1994_CD intakes_NNS ._SENT To_TO address_VB the_DT possibility_NN that_IN dietary_JJ changes_NNS caused_VBN by_IN early_JJ symptoms_NNS of_IN Parkinson_NP 's_POS disease_NN might_MD affect_VB the_DT results_NNS ,_, we_PP also_RB analyzed_VBD the_DT data_NNS by_IN excluding_VBG the_DT first_JJ 6_CD years_NNS of_IN follow-up_NN ._SENT RESULTS_VBZ TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP We_PP documented_VBD 191_CD incident_NN cases_NNS of_IN Parkinson_NP 's_POS disease_NN in_IN men_NNS and_CC 168_CD in_IN women_NNS ._SENT No_DT significant_JJ associations_NNS with_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN were_VBD observed_VBN for_IN baseline_JJ intakes_NNS of_IN energy_NN ,_, protein_NN ,_, carbohydrate_NN ,_, and_CC total_JJ fat_NN (_( table_NN 1_CD )_) ._SENT Higher_JJR baseline_NN intakes_NNS of_IN animal_JJ fat_JJ and_CC saturated_JJ fat_NN tended_VBN to_TO be_VB associated_VBN with_IN greater_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN in_IN men_NNS (_( relative_JJ risks_NNS (_( RR_NP )_) for_IN the_DT highest_JJS compared_VBN with_IN the_DT lowest_JJS quintiles_NNS =_SYM 1.42_CD and_CC 1.44_CD ,_, respectively_RB )_) ;_: however_RB ,_, neither_DT association_NN showed_VBD a_DT significant_JJ linear_JJ trend_NN (_( p_NN =_SYM 0.1_CD )_) ._SENT In_IN the_DT analyses_NNS in_IN which_WDT we_PP used_VBD baseline_JJ diet_NN but_CC excluded_VBD the_DT first_JJ 6_CD years_NNS of_IN follow-up_NN ,_, the_DT associations_NNS were_VBD attenuated_VBN (_( quintiles_NNS 1-5_CD :_: RR_NP =_SYM 1.0_CD (_( reference_NN )_) ,_, RR_NP =_SYM 0.92_CD ,_, RR_NP =_SYM 1.06_CD ,_, RR_NP =_SYM 0.89_CD ,_, and_CC RR_NP =_SYM 1.16_CD for_IN animal_JJ fat_NN (_( p_NN for_IN trend_NN =_SYM 0.7_CD )_) ;_: RR_NP =_SYM 1.0_CD ,_, RR_NP =_SYM 1.10_CD ,_, RR_NP =_SYM 1.35_CD ,_, RR_NP =_SYM 1.12_CD ,_, and_CC RR_NP =_SYM 1.30_CD for_IN saturated_JJ fat_NN (_( p_NN for_IN trend_NN =_SYM 0.4_CD )_) )_) ._SENT Both_DT associations_NNS were_VBD also_RB attenuated_VBN in_IN the_DT analyses_NNS in_IN which_WDT the_DT cumulative_JJ average_JJ intakes_NNS of_IN these_DT nutrients_NNS were_VBD used_VBN (_( quintiles_NNS 1-5_CD :_: RR_NP =_SYM 1.0_CD ,_, RR_NP =_SYM 0.98_CD ,_, RR_NP =_SYM 1.26_CD ,_, RR_NP =_SYM 0.84_CD ,_, and_CC RR_NP =_SYM 1.25_CD for_IN animal_JJ fat_NN (_( p_NN for_IN trend_NN =_SYM 0.5_CD )_) ;_: RR_NP =_SYM 1.0_CD ,_, RR_NP =_SYM 0.91_CD ,_, RR_NP =_SYM 1.26_CD ,_, RR_NP =_SYM 0.89_CD ,_, and_CC RR_NP =_SYM 1.19_CD for_IN saturated_JJ fat_NN (_( p_NN for_IN trend_NN =_SYM 0.5_CD )_) )_) ._SENT In_IN contrast_NN to_TO men_NNS ,_, a_DT nonsignificantly_RB lower_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD found_VBN among_IN women_NNS whose_WP$ intake_NN of_IN animal_NN or_CC saturated_JJ fat_NN was_VBD the_DT highest_JJS compared_VBN with_IN the_DT lowest_JJS (_( RR_NP =_SYM 0.65_CD ,_, 95_CD percent_NN confidence_NN interval_NN (_( CI_NP )_) :_: 0.36_CD ,_, 1.16_CD for_IN animal_JJ fat_NN ;_: RR_NP =_SYM 0.65_CD ,_, 95_CD percent_NN CI_NP :_: 0.37_CD ,_, 1.16_CD for_IN saturated_JJ fat_NN ,_, respectively_RB )_) ._SENT Similar_JJ results_NNS were_VBD found_VBN in_IN the_DT cumulative_JJ diet_NN analyses_NNS (_( RR_NP =_SYM 0.60_CD ,_, 95_CD percent_NN CI_NP :_: 0.33_CD ,_, 1.09_CD ;_: RR_NP =_SYM 0.69_CD ,_, 95_CD percent_NN CI_NP :_: 0.39_CD ,_, 1.22_CD ,_, respectively_RB )_) and_CC the_DT 6-year_JJ lag_NN analyses_NNS (_( RR_NP =_SYM 0.62_CD ,_, 95_CD percent_NN CI_NP :_: 0.34_CD ,_, 1.15_CD ;_: RR_NP =_SYM 0.63_CD ,_, 95_CD percent_NN CI_NP :_: 0.35_CD ,_, 1.15_CD ,_, respectively_RB )_) ._SENT View_VB this_DT table_NN :_: TABLE_NN 1_CD ._SENT Relative_JJ risks*_NN of_IN Parkinson_NP 's_POS disease_NN according_VBG to_TO quintile_NN of_IN baseline_JJ dietary_JJ intake_NN of_IN energy_NN ,_, protein_NN ,_, carbohydrate_NN ,_, and_CC total_JJ and_CC major_JJ types_NNS of_IN fat_NN among_IN US_NP men_NNS (_( 1986-1998_CD )_) and_CC women_NNS (_( 1980-1998_CD )_) Replacement_NN of_IN polyunsaturated_JJ fat_NN with_IN saturated_JJ fat_NN was_VBD associated_VBN with_IN a_DT significant_JJ increase_NN in_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN among_IN men_NNS ._SENT The_DT relative_JJ risk_NN for_IN a_DT 5_CD percent_NN energy_NN replacement_NN was_VBD 1.83_CD (_( 95_CD percent_NN CI_NP :_: 1.10_CD ,_, 3.03_CD )_) ._SENT However_RB ,_, the_DT association_NN was_VBD attenuated_VBN in_IN the_DT 6-year_JJ lag_NN analyses_NNS (_( RR_NP =_SYM 1.42_CD ,_, 95_CD percent_NN CI_NP :_: 0.71_CD ,_, 2.83_CD )_) ,_, and_CC no_DT such_JJ association_NN was_VBD observed_VBN among_IN women_NNS (_( RR_NP =_SYM 0.86_CD ,_, 95_CD percent_NN CI_NP :_: 0.54_CD ,_, 1.36_CD )_) ._SENT Baseline_JJ intakes_NNS of_IN monounsaturated_JJ fat_NN ,_, total_JJ polyunsaturated_JJ fat_NN ,_, trans-unsaturated_JJ fat_NN ,_, and_CC cholesterol_NN were_VBD not_RB significantly_RB associated_VBN with_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN (_( table_NN 1_CD )_) ;_: similarly_RB ,_, nonsignificant_JJ results_NNS were_VBD obtained_VBN in_IN the_DT cumulative_JJ update_NN and_CC 6-year_JJ lag_NN analyses_NNS ._SENT Because_IN of_IN the_DT different_JJ physiologic_JJ effects_NNS of_IN individual_JJ polyunsaturated_JJ fatty_JJ acids_NNS ,_, intakes_NNS were_VBD examined_VBN separately_RB (_( table_NN 2_CD )_) ._SENT No_DT significant_JJ associations_NNS were_VBD found_VBN between_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN and_CC intake_NN of_IN linoleic_NN ,_, {_( alpha_NN }_) -linolenic_JJ ,_, or_CC long-chain_NN {_( omega_NN }_) -3_CD fatty_NN acids_NNS ,_, including_VBG eicosapentaenoic_JJ acid_NN and_CC docosahexaenoic_JJ acid_NN ._SENT A_DT higher_JJR baseline_NN intake_NN of_IN arachidonic_JJ acid_NN tended_VBN to_TO be_VB associated_VBN with_IN a_DT lower_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN (_( pooled_VBN RR_NP for_IN the_DT highest_JJS vs._CC lowest_JJS intake_NN quintiles_NNS =_SYM 0.65_CD ,_, 95_CD percent_NN CI_NP :_: 0.46_CD ,_, 0.91_CD ;_: p_NN for_IN trend_NN =_SYM 0.05_CD )_) ,_, and_CC the_DT association_NN remained_VBD in_IN the_DT cumulative_JJ average_JJ analyses_NNS (_( pooled_VBN RR_NP =_SYM 0.62_CD ,_, 95_CD percent_NN CI_NP :_: 0.44_CD ,_, 0.88_CD ;_: p_NN for_IN trend_NN =_SYM 0.02_CD )_) ._SENT View_VB this_DT table_NN :_: TABLE_NN 2_CD ._SENT Relative_JJ risks*_NN of_IN Parkinson_NP 's_POS disease_NN according_VBG to_TO quintile_NN of_IN intake_NN of_IN major_JJ polyunsaturated_JJ fatty_JJ acids_NNS among_IN US_NP men_NNS (_( 1986-1998_CD )_) and_CC women_NNS (_( 1984-1998_CD )_) DISCUSSION_NP TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP In_IN these_DT large_JJ prospective_JJ studies_NNS ,_, we_PP did_VBD not_RB find_VB significant_JJ associations_NNS between_IN intakes_NNS of_IN total_JJ fat_JJ and_CC major_JJ types_NNS of_IN fat_NN and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT Although_IN men_NNS whose_WP$ intakes_NNS of_IN animal_JJ fat_JJ and_CC saturated_JJ fat_NN were_VBD higher_RBR tended_VBN to_TO have_VB a_DT greater_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN ,_, these_DT associations_NNS were_VBD not_RB statistically_RB significant_JJ in_IN the_DT more_JJR robust_JJ analyses_NNS based_VBN on_IN categories_NNS of_IN intake_NN and_CC were_VBD attenuated_VBN in_IN the_DT cumulative_JJ diet_NN and_CC 6-year_JJ lag_NN analyses_NNS ._SENT Arachidonic_JJ acid_JJ intake_NN showed_VBD a_DT marginally_RB significant_JJ inverse_JJ association_NN with_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT Both_CC the_DT Health_NP Professionals_NP Follow-up_NP Study_NP and_CC the_DT Nurses_NP '_POS Health_NP Study_NP were_VBD prospectively_RB designed_VBN ,_, with_IN repeated_VBN dietary_JJ assessments_NNS and_CC long_JJ follow-up_NN periods_NNS ._SENT Intakes_NNS of_IN total_JJ and_CC individual_JJ fats_NNS derived_VBN from_IN our_PP$ dietary_JJ questionnaires_NNS reasonably_RB reflected_VBD the_DT long-term_JJ fat_JJ intakes_NNS of_IN the_DT study_NN populations_NNS (_( 10_CD ,_, 11_CD ,_, 16-18_CD )_) and_CC have_VBP been_VBN found_VBN to_TO predict_VB the_DT risk_NN of_IN coronary_JJ heart_NN disease_NN in_IN a_DT manner_NN consistent_JJ with_IN their_PP$ metabolic_JJ effects_NNS (_( 21_CD ,_, 23_CD )_) ._SENT Previous_JJ epidemiologic_JJ results_NNS on_IN dietary_JJ fats_NNS and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN have_VBP been_VBN inconsistent_JJ ._SENT A_DT higher_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD found_VBN among_IN participants_NNS with_IN greater_JJR intakes_NNS of_IN total_JJ fat_NN (_( 4_CD ,_, 9_CD )_) ,_, animal_NN fat_NN (_( 4_CD )_) or_CC foods_NNS high_JJ in_IN animal_JJ fat_NN (_( 8_CD )_) ,_, or_CC cholesterol_NN (_( 9_CD )_) in_IN three_CD case-control_NN studies_NNS ,_, with_IN odds_NNS ratios_NNS ranging_VBG from_IN 2_CD to_TO 5_CD for_IN the_DT highest_JJS compared_VBN with_IN the_DT lowest_JJS categories_NNS ._SENT However_RB ,_, these_DT studies_NNS were_VBD retrospectively_RB designed_VBN ,_, and_CC each_DT included_VBD fewer_JJR than_IN 130_CD cases_NNS ._SENT In_IN a_DT larger_JJR case-control_NN study_NN (_( 342_CD cases_NNS )_) (_( 5_LS )_) and_CC a_DT small_JJ prospective_JJ study_NN among_IN Hawaiian_JJ men_NNS (_( 84_CD cases_NNS )_) (_( 6_CD )_) ,_, null_JJ associations_NNS between_IN total_JJ or_CC animal_JJ fat_JJ intake_NN and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN were_VBD reported_VBN ._SENT Compared_VBN with_IN animal_JJ fat_NN ,_, vegetable_NN fat_NN and_CC polyunsaturated_JJ fatty_JJ acids_NNS have_VBP been_VBN evaluated_VBN less_RBR often_RB ._SENT Two_CD of_IN these_DT previous_JJ case-control_NN studies_NNS (_( 4_CD ,_, 9_CD )_) and_CC the_DT prospective_JJ investigation_NN (_( 6_CD )_) have_VBP reported_VBN null_JJ associations_NNS between_IN linoleic_JJ acid_NN or_CC vegetable_NN fat_NN intakes_NNS and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT Although_IN a_DT slightly_RB greater_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD found_VBN among_IN men_NNS in_IN the_DT current_JJ study_NN whose_WP$ intake_NN of_IN animal_NN or_CC saturated_JJ fat_NN was_VBD higher_JJR ,_, the_DT increment_NN was_VBD in_IN the_DT range_NN of_IN random_JJ error_NN ,_, and_CC the_DT association_NN was_VBD attenuated_VBN in_IN further_JJR analyses_NNS ._SENT Moreover_RB ,_, a_DT nonsignificantly_RB lower_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN was_VBD found_VBN among_IN women_NNS in_IN the_DT highest_JJS quintile_NN of_IN animal_NN or_CC saturated_JJ fat_JJ intake_NN compared_VBN with_IN those_DT in_IN the_DT lowest_JJS quintile_NN ._SENT The_DT greater_JJR risk_NN of_IN Parkinson_NP 's_POS disease_NN associated_VBN with_IN isocaloric_JJ replacement_NN of_IN saturated_JJ fat_NN with_IN polyunsaturated_JJ fat_NN by_IN men_NNS was_VBD probably_RB a_DT result_NN of_IN its_PP$ weak_JJ positive_JJ association_NN with_IN saturated_JJ fat_JJ and_CC inverse_JJ association_NN with_IN polyunsaturated_JJ fat_NN ._SENT Therefore_RB ,_, although_IN we_PP could_MD not_RB rule_VB out_RP the_DT hypothesis_NN that_IN dietary_JJ intakes_NNS of_IN animal_NN or_CC saturated_JJ fat_NN in_IN adult_JJ life_NN increase_VB the_DT risk_NN of_IN Parkinson_NP 's_POS disease_NN ,_, our_PP$ results_NNS do_VBP not_RB strongly_RB support_VB it_PP ._SENT Intakes_NNS of_IN most_JJS polyunsaturated_JJ fatty_JJ acids_NNS were_VBD not_RB associated_VBN with_IN risk_NN of_IN Parkinson_NP 's_POS disease_NN in_IN this_DT study_NN ._SENT However_RB ,_, we_PP found_VBD an_DT inverse_JJ association_NN between_IN arachidonic_JJ acid_JJ intake_NN and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN among_IN women_NNS and_CC a_DT similar_JJ ,_, but_CC nonsignificant_JJ association_NN among_IN men_NNS ._SENT Arachidonic_JJ acid_NN has_VBZ important_JJ physiologic_JJ functions_NNS in_IN the_DT central_JJ nervous_JJ system_NN (_( 24_CD )_) and_CC can_MD stimulate_VB dopamine_NN release_NN and_CC inhibit_VB its_PP$ reuptake_NN in_IN the_DT rat_NN striatum_NN (_( 25_CD )_) ;_: however_RB ,_, the_DT relevance_NN of_IN this_DT experimental_JJ finding_NN to_TO human_JJ Parkinson_NPS 's_POS disease_NN is_VBZ not_RB clear_JJ ,_, and_CC we_PP cannot_MD exclude_VB the_DT possibility_NN that_IN our_PP$ arachidonic_JJ acid_NN results_NNS were_VBD due_JJ to_TO chance_NN ._SENT Dietary_JJ fatty_JJ acids_NNS have_VBP been_VBN hypothesized_VBN to_TO increase_VB the_DT risk_NN of_IN Parkinson_NP 's_POS disease_NN because_IN they_PP can_MD potentially_RB contribute_VB to_TO the_DT oxidative_JJ stress_NN that_WDT has_VBZ been_VBN implicated_VBN in_IN Parkinson_NP 's_POS disease_NN pathogenesis_NN ._SENT Neural_JJ membranes_NNS are_VBP rich_JJ in_IN polyunsaturated_JJ fatty_JJ acids_NNS ,_, which_WDT are_VBP good_JJ substrates_NNS for_IN the_DT oxidative_JJ radicals_NNS ._SENT Cascades_NNS of_IN lipid_NN peroxidation_NN will_MD cause_VB further_RBR oxidative_JJ damage_NN and_CC adversely_RB modify_VB the_DT lipid_NN composition_NN of_IN membranes_NNS ,_, possibly_RB contributing_VBG to_TO neuron_NN death_NN (_( 26_CD )_) ._SENT In_IN addition_NN ,_, adverse_JJ essential_JJ fatty_JJ acid_NN composition_NN of_IN mitochondrial_JJ membrane_NN may_MD also_RB induce_VB phosphorylation_NN uncoupling_VBG ,_, resulting_VBG in_IN energy_NN failure_NN (_( 27_CD )_) ._SENT Some_DT support_NN for_IN lipid_NN peroxidation_NN in_IN Parkinson_NP 's_POS disease_NN is_VBZ found_VBN among_IN persons_NNS who_WP died_VBD of_IN the_DT disease_NN ._SENT Compared_VBN with_IN controls_NNS ,_, these_DT persons_NNS had_VBD higher_JJR concentrations_NNS of_IN polyunsaturated_JJ fatty_JJ acid_JJ peroxidation_NN metabolites_NNS but_CC lower_JJR concentrations_NNS of_IN polyunsaturated_JJ fatty_JJ acids_NNS and_CC glutathione_NN in_IN the_DT substantia_NN nigra_NN (_( 28-32_CD )_) ._SENT Saturated_JJ fat_NN could_MD modify_VB the_DT risk_NN of_IN Parkinson_NP 's_POS disease_NN by_IN affecting_VBG polyunsaturated_JJ fatty_JJ acid_NN metabolism_NN and_CC inducing_VBG adverse_JJ changes_NNS in_IN cell_NN membrane_NN lipid_NN composition_NN (_( 27_CD )_) ,_, but_CC these_DT potential_JJ mechanisms_NNS remain_VBP speculative_JJ ._SENT Lower_JJR energy_NN intake_NN may_MD decrease_VB free-radical_JJ production_NN in_IN the_DT mitochondria_NNS ,_, and_CC experimental_JJ studies_NNS have_VBP shown_VBN that_IN energy_NN restriction_NN made_VBD the_DT midbrain_NN dopaminergic_NN neurons_NNS more_RBR resistant_JJ to_TO the_DT N-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine_NP (_( MPTP_NP )_) neurotoxicity_NN (_( 33_CD )_) ._SENT Two_CD case-control_NN studies_NNS and_CC one_CD clinical_JJ observation_NN found_VBD that_IN Parkinson_NP 's_POS disease_NN patients_NNS reported_VBD higher_JJR energy_NN intakes_NNS than_IN controls_NNS (_( 3-5_CD )_) ._SENT However_RB ,_, as_RB noted_VBD by_IN the_DT authors_NNS (_( 34_CD )_) ,_, higher_JJR energy_NN intake_NN might_MD be_VB a_DT consequence_NN of_IN the_DT disease_NN because_IN of_IN the_DT higher_JJR energy_NN expenditure_NN associated_VBN with_IN rigidity_NN and_CC tremor_NN in_IN Parkinson_NP 's_POS disease_NN patients_NNS ._SENT In_IN this_DT prospective_JJ study_NN ,_, we_PP did_VBD not_RB find_VB any_DT evidence_NN to_TO support_VB that_DT higher_JJR energy_NN intake_NN increases_VBZ risk_NN of_IN Parkinson_NP 's_POS disease_NN ,_, nor_CC did_VBD we_PP find_VBP any_DT evidence_NN to_TO support_VB a_DT previous_JJ case-control_NN finding_VBG that_DT carbohydrate_NN intake_NN is_VBZ positively_RB associated_VBN with_IN Parkinson_NP 's_POS disease_NN risk_NN (_( 5_CD )_) ._SENT Potential_JJ limitations_NNS of_IN this_DT study_NN include_VBP errors_NNS in_IN outcome_NN and_CC exposure_NN assessments_NNS ._SENT For_IN the_DT diagnosis_NN of_IN Parkinson_NP 's_POS disease_NN ,_, we_PP relied_VBD on_IN the_DT judgment_NN of_IN the_DT patients_NNS '_POS treating_VBG physicians_NNS ,_, in_IN most_JJS cases_NNS their_PP$ neurologists_NNS ._SENT Since_IN we_PP did_VBD not_RB have_VB a_DT pathologic_JJ confirmation_NN ,_, we_PP cannot_MD exclude_VB the_DT possibility_NN that_IN a_DT few_JJ cases_NNS were_VBD misdiagnosed_VBN ._SENT However_RB ,_, the_DT results_NNS of_IN a_DT recent_JJ clinicopathologic_JJ study_NN (_( 35_CD )_) suggest_VBP that_IN the_DT clinical_JJ Parkinson_NP diagnosis_NN (_( made_VBN by_IN a_DT neurologist_NN in_IN 86_CD percent_NN of_IN their_PP$ case_NN series_NN )_) is_VBZ accurate_JJ in_IN 90_CD percent_NN of_IN the_DT cases_NNS ._SENT The_DT bias_NN resulting_VBG from_IN this_DT source_NN is_VBZ therefore_RB likely_JJ to_TO have_VB been_VBN small_JJ ._SENT The_DT null_JJ results_NNS of_IN our_PP$ study_NN could_MD also_RB be_VB explained_VBN by_IN error_NN in_IN assessing_VBG fat_JJ intakes_NNS ._SENT Although_IN some_DT error_NN dietary_NN assessment_NN was_VBD inevitable_JJ in_IN this_DT as_RB well_RB as_IN in_IN previous_JJ studies_NNS ,_, we_PP minimized_VBD it_PP by_IN using_VBG an_DT extensively_RB validated_VBN FFQ_NP and_CC repeated_JJ dietary_JJ assessments_NNS ._SENT Nevertheless_RB ,_, modest_JJ or_CC weak_JJ associations_NNS cannot_MD be_VB excluded_VBN ._SENT Finally_RB ,_, because_IN the_DT cohort_NN participants_NNS were_VBD well-educated_JJ health_NN professionals_NNS and_CC not_RB a_DT random_JJ sample_NN of_IN the_DT US_NP general_JJ population_NN ,_, our_PP$ results_NNS may_MD not_RB apply_VB to_TO persons_NNS whose_WP$ fat_JJ intakes_NNS are_VBP outside_IN the_DT range_NN of_IN the_DT current_JJ study_NN or_CC those_DT who_WP otherwise_RB have_VBP markedly_RB different_JJ dietary_JJ habits_NNS ._SENT In_IN summary_NN ,_, our_PP$ study_NN lends_VBZ little_RB support_VB to_TO the_DT hypothesis_NN that_IN higher_JJR fat_JJ intakes_NNS increase_NN risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT The_DT results_NNS suggest_VBP a_DT possible_JJ adverse_JJ effect_NN of_IN replacing_VBG polyunsaturated_JJ fat_NN with_IN saturated_JJ fat_NN for_IN men_NNS and_CC a_DT potential_JJ beneficial_JJ effect_NN of_IN arachidonic_JJ acid_NN ,_, but_CC these_DT findings_NNS are_VBP preliminary_JJ and_CC require_VB further_JJR evaluation_NN ._SENT ACKNOWLEDGMENTS_NNS This_DT study_NN was_VBD supported_VBN by_IN research_NN grants_NNS NS35624_NP and_CC CA87969_NP from_IN the_DT National_NP Institutes_NPS of_IN Health_NP ,_, Bethesda_NP ,_, Maryland_NP ,_, and_CC a_DT gift_NN from_IN the_DT Kinetics_NP Foundation_NP ._SENT The_DT authors_NNS thank_VBP Drs._NP Frank_NP E._NP Speizer_NP and_CC Graham_NP A._NP Colditz_NP ,_, the_DT principal_JJ investigators_NNS of_IN the_DT Nurses_NP '_POS Health_NP Study_NP ._SENT They_PP also_RB thank_VBP Al_NP Wing_NP ,_, Karen_NP Corsano_NP ,_, Laura_NP Sampson_NP ,_, Gary_NP Chase_NP ,_, Barbara_NP Egan_NP ,_, Mira_NP Kaufman_NP ,_, Betsy_NP Frost-Hawes_NP ,_, Stacey_NP DeCaro_NP ,_, and_CC Mitzi_NP Wolff_NP for_IN their_PP$ technical_JJ help_NN ._SENT NOTES_VBZ Correspondence_NP to_TO Dr._NP Honglei_NP Chen_NP ,_, Department_NP of_IN Nutrition_NP ,_, Harvard_NP School_NP of_IN Public_NP Health_NP ,_, 665_CD Huntington_NP Avenue_NP ,_, Boston_NP ,_, MA_NP 02115_CD (_( e-mail_NP :_: hchen{at}hsph.harvard.edu_NP )_) ._SENT Back_RB REFERENCES_NP TOP_NP ABSTRACT_NP INTRODUCTION_NP MATERIALS_NP AND_CC METHODS_NP RESULTS_NP DISCUSSION_NP REFERENCES_NP 1_CD ._SENT Jenner_NP P_NN ,_, Olanow_NP CW_NP ._SENT Understanding_VBG cell_NN death_NN in_IN Parkinson_NP 's_POS disease_NN ._SENT Ann_NP Neurol_NP 1998_CD ;_: 44:S72-84.[ISI][Medline_NP ]_SYM 2_CD ._SENT Jenner_NP P_NN ,_, Olanow_NP CW_NP ._SENT Oxidative_JJ stress_NN and_CC the_DT pathogenesis_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT Neurology_NN 1996_CD ;_: 47:S161-70.[Abstract_NN ]_SYM 3_CD ._SENT Davies_NP KN_NP ,_, King_NP D_NP ,_, Davies_NP H._NP A_DT study_NN of_IN the_DT nutritional_JJ status_NN of_IN elderly_JJ patients_NNS with_IN Parkinson_NP 's_POS disease_NN ._SENT Age_NN Ageing_NP 1994_CD ;_: 23:142-5.[Abstract_NN ]_SYM 4_CD ._SENT Logroscino_NP G_NP ,_, Marder_NP K_NP ,_, Cote_NP L_NP ,_, et_FW al._FW Dietary_JJ lipids_NNS and_CC antioxidants_NNS in_IN Parkinson_NP 's_POS disease_NN :_: a_DT population-based_JJ ,_, case-control_NN study_NN ._SENT Ann_NP Neurol_NP 1996_CD ;_: 39:89-94.[ISI][Medline_NP ]_SYM 5_CD ._SENT Hellenbrand_NP W_NP ,_, Boeing_NP H_NP ,_, Robra_NP BP_NP ,_, et_FW al._FW Diet_NP and_CC Parkinson_NP 's_POS disease_NN ._SENT II_NP :_: a_DT possible_JJ role_NN for_IN the_DT past_JJ intake_NN of_IN specific_JJ nutrients_NNS ._SENT Results_NNS from_IN a_DT self-administered_VBN food-frequency_NN questionnaire_NN in_IN a_DT case-control_NN study_NN ._SENT Neurology_NN 1996_CD ;_: 47:644-50.[Abstract_NN ]_SYM 6_CD ._SENT Morens_NP DM_NP ,_, Grandinetti_NP A_NP ,_, Waslien_NP CI_NP ,_, et_FW al._FW Case-control_NP study_NN of_IN idiopathic_NP Parkinson_NP 's_POS disease_NN and_CC dietary_JJ vitamin_NN E_NN intake_NN ._SENT Neurology_NN 1996_CD ;_: 46:1270-4.[Abstract_NN ]_SYM 7_CD ._SENT Logroscino_NP G_NP ,_, Marder_NP K_NP ,_, Graziano_NP J_NP ,_, et_FW al._FW Dietary_NP iron_NN ,_, animal_NN fats_NNS ,_, and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN ._SENT Mov_NP Disord_NP 1998_CD ;_: 13:13-16.[ISI][Medline_NP ]_SYM 8_CD ._SENT Anderson_NP C_NP ,_, Checkoway_NP H_NP ,_, Franklin_NP GM_NP ,_, et_FW al._FW Dietary_JJ factors_NNS in_IN Parkinson_NP 's_POS disease_NN :_: the_DT role_NN of_IN food_NN groups_NNS and_CC specific_JJ foods_NNS ._SENT Mov_NP Disord_NP 1999_CD ;_: 14:21-7.[CrossRef][ISI][Medline_NP ]_SYM 9_CD ._SENT Johnson_NP CC_NP ,_, Gorell_NP JM_NP ,_, Rybicki_NP BA_NP ,_, et_FW al._FW Adult_JJ nutrient_JJ intake_NN as_IN a_DT risk_NN factor_NN for_IN Parkinson_NP 's_POS disease_NN ._SENT Int_NP J_NP Epidemiol_NP 1999_CD ;_: 28:1102-9.[Abstract_NN ]_SYM 10_CD ._SENT Willett_NP WC_NN ._SENT Nutritional_JJ epidemiology_NN ._SENT New_NP York_NP ,_, NY_NP :_: Oxford_NP University_NP Press_NP ,_, 1998_CD ._SENT 11_CD ._SENT Rimm_NP EB_NP ,_, Giovannucci_NP EL_NP ,_, Stampfer_NP MJ_NP ,_, et_FW al._FW Reproducibility_NN and_CC validity_NN of_IN an_DT expanded_JJ self-administered_VBN semiquantitative_JJ food_NN frequency_NN questionnaire_NN among_IN male_JJ health_NN professionals_NNS ._SENT Am_NP J_NP Epidemiol_NP 1992_CD ;_: 135:1114-26.[Abstract_NP ]_SYM 12_CD ._SENT Colditz_NP GA_NP ,_, Manson_NP JE_NP ,_, Hankinson_NP SE_NP ._SENT The_DT Nurses_NP '_POS Health_NP Study_NP :_: 20-year_JJ contribution_NN to_TO the_DT understanding_NN of_IN health_NN among_IN women_NNS ._SENT J_NP Womens_NP Health_NP 1997_CD ;_: 6:49-62.[ISI][Medline_NP ]_SYM 13_CD ._SENT Ascherio_NP A_NP ,_, Zhang_NP SM_NP ,_, Hern√°n_NP MA_NP ,_, et_FW al._FW Prospective_JJ study_NN of_IN caffeine_NN consumption_NN and_CC risk_NN of_IN Parkinson_NP 's_POS disease_NN in_IN men_NNS and_CC women_NNS ._SENT Ann_NP Neurol_NP 2001_CD ;_: 50:56-63.[CrossRef][ISI][Medline_NP ]_SYM 14_CD ._SENT US_NP Department_NP of_IN Agriculture_NP ._SENT Composition_NN of_IN foods_NNS :_: raw_JJ ,_, processed_JJ ,_, prepared_JJ ,_, 1963-1988_CD ._SENT Washington_NP ,_, DC_NP :_: US_NP Department_NP of_IN Agriculture_NP ,_, 1989_CD ._SENT 15_CD ._SENT US_NP Department_NP of_IN Agriculture_NP ,_, Agriculture_NP Research_NP Service_NP ._SENT USDA_NP nutrient_JJ database_NN for_IN standard_JJ reference_NN ,_, release_NN 10_CD ._SENT Nutrient_JJ data_NNS laboratory_NN home_NN page_NN ,_, 1993_CD (_( http://www.nal.usda.gov/fnic/foodcomp_NN )_) ._SENT 16_LS ._SENT Willett_NP WC_NN ,_, Sampson_NP L_NP ,_, Stampfer_NP MJ_NP ,_, et_FW al._FW Reproducibility_NN and_CC validity_NN of_IN a_DT semiquantitative_JJ food_NN frequency_NN questionnaire_NN ._SENT Am_NP J_NP Epidemiol_NP 1985_CD ;_: 122:51-65.[Abstract_NP ]_SYM 17_CD ._SENT Hunter_NP DJ_NP ,_, Rimm_NP EB_NP ,_, Sacks_NP FM_NP ,_, et_FW al._FW Comparison_NN of_IN measures_NNS of_IN fatty_JJ acid_JJ intake_NN by_IN subcutaneous_JJ fat_JJ aspirate_NN ,_, food_NN frequency_NN questionnaire_NN ,_, and_CC diet_NN records_NNS in_IN a_DT free-living_JJ population_NN of_IN US_NP men_NNS ._SENT Am_NP J_NP Epidemiol_NP 1992_CD ;_: 135:418-27.[Abstract_NP ]_SYM 18_CD ._SENT Garland_NP M_NP ,_, Sacks_NP FM_NP ,_, Colditz_NP GA_NP ,_, et_FW al._FW The_DT relation_NN between_IN dietary_JJ intake_NN and_CC adipose_JJ tissue_NN composition_NN of_IN selected_JJ fatty_JJ acids_NNS in_IN US_NP women_NNS ._SENT Am_NP J_NP Clin_NP Nutr_NP 1998_CD ;_: 67:25-30.[Abstract_NN ]_SYM 19_CD ._SENT Rothman_NP KJ_NP ,_, Greenland_NP S_NP ,_, eds_NNS ._SENT Modern_JJ epidemiology_NN ._SENT 2nd_JJ ed_NN ._SENT Philadelphia_NP ,_, PA_NP :_: Lippincott-Raven_NP ,_, 1998_CD ._SENT 20_CD ._SENT D'Agostino_NP RB_NP ,_, Lee_NP ML_NP ,_, Belanger_NP AJ_NP ,_, et_FW al._FW Relation_NN of_IN pooled_JJ logistic_JJ regression_NN to_TO time_VB dependent_JJ Cox_NP regression_NN analysis_NN :_: the_DT Framingham_NP Heart_NP Study_NP ._SENT Stat_NP Med_NP 1990_CD ;_: 9:1501-15.[ISI][Medline_NN ]_SYM 21_CD ._SENT Hu_NP FB_NP ,_, Stampfer_NP MJ_NP ,_, Manson_NP JE_NP ,_, et_FW al._FW Dietary_NP fat_JJ intake_NN and_CC the_DT risk_NN of_IN coronary_JJ heart_NN disease_NN in_IN women_NNS ._SENT N_NP Engl_NP J_NP Med_NP 1997_CD ;_: 337:1491-9.[Abstract/Free_JJ Full_JJ Text_NN ]_SYM 22_CD ._SENT Hu_NP FB_NP ,_, Stampfer_NP MJ_NP ,_, Rimm_NP E_NP ,_, et_FW al._FW Dietary_JJ fat_JJ and_CC coronary_JJ heart_NN disease_NN :_: a_DT comparison_NN of_IN approaches_NNS for_IN adjusting_VBG for_IN total_JJ energy_NN intake_NN and_CC modeling_VBG repeated_JJ dietary_JJ measurements_NNS ._SENT Am_NP J_NP Epidemiol_NP 1999_CD ;_: 149:531-40.[Abstract_NP ]_SYM 23_CD ._SENT Ascherio_NP A_NP ,_, Rimm_NP EB_NP ,_, Giovannucci_NP EL_NP ,_, et_FW al._FW Dietary_NP fat_NN and_CC risk_NN of_IN coronary_JJ heart_NN disease_NN in_IN men_NNS :_: cohort_NN follow_VB up_RP study_NN in_IN the_DT United_NP States_NPS ._SENT BMJ_NP 1996_CD ;_: 313:84-90.[Abstract/Free_JJ Full_JJ Text_NN ]_SYM 24_CD ._SENT Youdim_NP KA_NP ,_, Martin_NP A_NP ,_, Joseph_NP JA_NP ._SENT Essential_JJ fatty_JJ acids_NNS and_CC the_DT brain_NN :_: possible_JJ health_NN implications_NNS ._SENT Int_NP J_NP Dev_NP Neurosci_NP 2000_CD ;_: 18:383-99.[CrossRef][ISI][Medline_NP ]_SYM 25_CD ._SENT L'Hirondel_NP M_NP ,_, Cheramy_NP A_NP ,_, Godeheu_NP G_NP ,_, et_FW al._FW Effects_NNS of_IN arachidonic_JJ acid_NN on_IN dopamine_NN synthesis_NN ,_, spontaneous_JJ release_NN ,_, and_CC uptake_NN in_IN striatal_JJ synaptosomes_NNS from_IN the_DT rat_NN ._SENT J_NP Neurochem_NP 1995_CD ;_: 64:1406-9.[ISI][Medline_NP ]_SYM 26_CD ._SENT Farooqui_NP AA_NP ,_, Horrocks_NP LA_NP ._SENT Lipid_NN peroxides_NNS in_IN the_DT free_JJ radical_JJ pathophysiology_NN of_IN brain_NN diseases_NNS ._SENT Cell_NN Mol_NP Neurobiol_NP 1998_CD ;_: 18:599-608.[CrossRef][ISI][Medline_NP ]_SYM 27_CD ._SENT Peers_NP R._NP Fatty_NP diet_NN ,_, mitochondria_NNS and_CC Parkinson_NP 's_POS disease_NN ._SENT (_( Letter_NN )_) ._SENT N_NP Z_NP Med_NP J_NP 1997_CD ;_: 110:132_CD ._SENT 28_CD ._SENT Dexter_NP DT_NP ,_, Carter_NP CJ_NP ,_, Wells_NP FR_NP ,_, et_FW al._FW Basal_JJ lipid_NN peroxidation_NN in_IN substantia_NN nigra_NN is_VBZ increased_VBN in_IN Parkinson_NP 's_POS disease_NN ._SENT J_NP Neurochem_NP 1989_CD ;_: 52:381-9.[ISI][Medline_NP ]_SYM 29_CD ._SENT Riederer_NP P_NN ,_, Sofic_NP E_NP ,_, Rausch_NP WD_NP ,_, et_FW al._FW Transition_NN metals_NNS ,_, ferritin_NN ,_, glutathione_NN ,_, and_CC ascorbic_JJ acid_NN in_IN parkinsonian_JJ brains_NNS ._SENT J_NP Neurochem_NP 1989_CD ;_: 52:515-20.[ISI][Medline_NP ]_SYM 30_CD ._SENT Dexter_NP DT_NP ,_, Holley_NP AE_NP ,_, Flitter_NP WD_NP ,_, et_FW al._FW Increased_JJ levels_NNS of_IN lipid_NN hydroperoxides_NNS in_IN the_DT parkinsonian_JJ substantia_NN nigra_NN :_: an_DT HPLC_NP and_CC ESR_NP study_NN ._SENT Mov_NP Disord_NP 1994_CD ;_: 9:92-7.[ISI][Medline_NN ]_SYM 31_CD ._SENT Yoritaka_NP A_NP ,_, Hattori_NP N_NP ,_, Uchida_NP K_NP ,_, et_FW al._FW Immunohistochemical_JJ detection_NN of_IN 4-hydroxynonenal_JJ protein_NN adducts_VBZ in_IN Parkinson_NP disease_NN ._SENT Proc_NP Natl_NP Acad_NP Sci_NP U_NP S_NP A_NP 1996_CD ;_: 93:2696-701.[Abstract/Free_JJ Full_JJ Text_NN ]_SYM 32_CD ._SENT Pearce_NP RK_NP ,_, Owen_NP A_NP ,_, Daniel_NP S_NP ,_, et_FW al._FW Alterations_NNS in_IN the_DT distribution_NN of_IN glutathione_NN in_IN the_DT substantia_NN nigra_NN in_IN Parkinson_NP 's_POS disease_NN ._SENT J_NP Neural_NP Transm_NP 1997_CD ;_: 104:661-77.[ISI_NP ]_SYM 33_CD ._SENT Duan_NP W_NP ,_, Mattson_NP MP_NN ._SENT Dietary_JJ restriction_NN and_CC 2-deoxyglucose_JJ administration_NN improve_VB behavioral_JJ outcome_NN and_CC reduce_VB degeneration_NN of_IN dopaminergic_NN neurons_NNS in_IN models_NNS of_IN Parkinson_NP 's_POS disease_NN ._SENT J_NP Neurosci_NP Res_NP 1999_CD ;_: 57:195-206.[CrossRef][ISI][Medline_NP ]_SYM 34_CD ._SENT Logroscino_NP G_NP ,_, Mayeux_NP R._NP Diet_NP and_CC Parkinson_NP 's_POS disease_NN ._SENT (_( Letter_VB ;_: comment_VB )_) ._SENT Neurology_NN 1997_CD ;_: 49:310-11.[ISI][Medline_NP ]_SYM 35_CD ._SENT Hughes_NP AJ_NP ,_, Daniel_NP SE_NP ,_, Lees_NP AJ_NP ._SENT Improved_VBN accuracy_NN of_IN clinical_JJ diagnosis_NN of_IN Lewy_NP body_NN Parkinson_NP 's_POS disease_NN ._SENT Neurology_NN 2001_CD ;_: 57:1497-9.[Abstract/Free_JJ Full_JJ Text_NN ]_SYM 